Zobrazeno 1 - 10
of 51
pro vyhledávání: ''
Autor:
Emad A. Rakha, David M. Heery, Cíntia J. Monteiro, Kartikeya Bhardwaj, Nigel P. Mongan, Wilbert Zwart, Mansour Alsaleem, Steffi Oesterreich, Takaaki Fujii, Ian O. Ellis, Andrew R. Green, Stacey E. P. Joosten, Sasagu Kurozumi, Ken Shirabe, Simon J Johnston
Publikováno v:
Cancer Research. 81:PS6-11
Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancer and is typically ER+ and ERBB2 non-amplified. There is preclinical evidence that somatic ERBB2 mutation may provide an alternative and tractable mechanism for upregulation
Autor:
Winfried R. Mulder, Lisa D. Eli, Neil T Conlon, Denis M. Collins, Suzanne J.C. van Gerwen, Alshad S. Lalani, Jeffrey J. Kooijman, Irmina Diala, John Crown, Guido J.R. Zaman
Publikováno v:
Cancer Research. 81:PS10-06
Introduction: Human epidermal growth factor 2 (HER2/ERBB2) is frequently amplified or mutated across various cancer types. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive b
Autor:
Mariaelena Pierobon, Leslie S L Kim, Lance A. Liotta, Maren K Levin, Emanuel F. Petricoin, Elisa Baldelli, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P4-10
Background: ER- HER2+ BC is comprised of a heterogeneous mix of intrinsic BC subtypes which have differential responsiveness to preop HER2-directed therapies combined with chemotherapy. Patients (pts) with ER- HER2+ BC whose disease progressed while
Autor:
Sri HariKrishna Vellanki, Mattia Cremona, Saraswati Sukumar, Alexander Casucci, Ciara Flynn, Yvonne E. Smith, Lance Hudson, Ann M. Hopkins, Kieran Brennan, Guannan Wang
Publikováno v:
Cancer Research. 80:P3-06
Background/Aim: Increased expression of the cell-cell adhesion molecule Junctional Adhesion Molecule-A (JAM-A) has been associated with poor prognosis and HER2 expression in patients with invasive ductal breast cancera,b. However, little is known abo
Autor:
Shinji Kohsaka, Masahito Kawazu, Kanju Saka, Shinya Kojima, Masaaki Nagano, Hirotaro Iwase, Hiroyuki Mano, Toshihide Ueno
Publikováno v:
Clinical Cancer Research. 24:5112-5122
Purpose: The advent of next-generation sequencing technologies has enabled the identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) among various cancers. However, the significance of infrequent mutations has no
Autor:
Gregory Sliwoski, Jie He, Jens Meiler, Daniel J. Zabransky, Dan Ye, Ariella B. Hanker, CL Arteaga, Vincent A. Miller, Sarah Croessmann, James P. Koch, Lisa N. Kinch, Alshad S. Lalani, Richard E. Cutler, M Red Brewer, Jonathan H. Sheehan
Publikováno v:
Cancer Research. 79:PD3-05
ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against breast cancers harboring HER2 activating mutations, suggesting these tumors depend on HER2 signaling
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/
Autor:
Jonathan H. Sheehan, Carlos L. Arteaga, Michael F. Berger, James P. Koch, Richard E. Cutler, Vincent A. Miller, Ariella B. Hanker, Rebecca J. Nagy, Gregory Sliwoski, David M. Hyman, Christine M. Lovly, Jie He, Alshad S. Lalani, Jens Meiler, Monica Red Brewer, David B. Solit, Richard B. Lanman, Darren Cross
Publikováno v:
Cancer Discovery. 7:575-585
We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization w
Autor:
Wen Jia Zuo, Zhi Ming Shao, Jiong Wu, Guang Yu Liu, Yi-Zhou Jiang, Gen Hong Di, Xin Hu, Y. Wang, Ke Da Yu, Xiao En Xu
Publikováno v:
Clinical Cancer Research. 22:4859-4869
Purpose: Somatic mutations in the tyrosine kinase domain of human epidermal growth factor receptor 2 (HER2) may be an alternative mechanism to HER2 activation and can affect the sensitivity toward HER2-targeted therapies. We aimed to investigate the
Autor:
Ilaria Conti, Sheng-Bin Peng, James J. Starling, Igor Mochalkin, Henry James Robert, Sean Buchanan, Robert D. Van Horn, Lysiane Huber, Gregory D. Plowman, Swee Seong Wong, Youyan Zhang, Vipin Yadav, Yong Gang Yue, Shih-Hsun Chen, Tinggui Yin
Publikováno v:
Cancer Discovery. 6:300-315
We have identified previously undiscovered BRAF in-frame deletions near the αC-helix region of the kinase domain in pancreatic, lung, ovarian, and thyroid cancers. These deletions are mutually exclusive with KRAS mutations and occur in 4.21% of KRAS